Blood test for ovarian cancer misses some Black and Native American patients, study finds
A common blood test may miss ovarian cancer in some Black and Native American patients, delaying their treatment, a new study finds. It's the latest example of medical tests that contribute to health care disparities.
Researchers have been working to uncover these kinds of biases in medicine. Recently, the Trump administration's crackdown on diversity, equity and inclusion has jeopardized such research as universities react to political pressure and federal agencies comb through grants looking for projects that violate the president's orders.
Native American women have the highest rate of ovarian cancer. Black women with ovarian cancer have lower rates of survival compared to white women. Finding ovarian cancer early can lead to better chances of survival.
The new study, supported by grants from the National Cancer Institute and published Thursday in JAMA Network Open, looked at a test called CA-125. The test measures a tumor marker in the blood, and doctors use it to determine if a woman with a suspicious lump should be referred to a cancer specialist.
Doctors depend on the test during early evaluations, so understanding what the results mean for people of different races and ethnicities is critical, said Dr. Shannon Westin of MD Anderson Cancer Center in Houston, who was not involved in the research.
'This is a perfect example of work that absolutely needed to be stratified based on race and ethnicity,' Westin said. The findings alert doctors that they shouldn't be totally reassured by a normal test result, she said.
So far, it's unknown why the test doesn't perform uniformly across groups. The researchers suspect it has something to do with a harmless genetic variation that is more common in people of African, Caribbean, Middle Eastern and West Indian descent.
Initial studies of the test, published in the 1980s, didn't record people's races but were in mostly white populations.
The test isn't perfect for white women either, said lead author Dr. Anna Jo Smith of the University of Pennsylvania's medical school.
'But if we have worse performance in certain groups, then we may be further contributing to disparities in referral, disparities in treatment, and ultimately we may be contributing to the lower survival in Black women with ovarian cancer,' Smith said.
The researchers analyzed data from more than 200,000 women with ovarian cancer from 2004 through 2020 who'd had a CA-125 blood test.
Black and Native American patients were 23% less likely to have an elevated CA-125 level at ovarian cancer diagnosis compared with white patients, suggesting the current thresholds are set too high.
The researchers also found that patients with false negative results started chemotherapy on average nine days later than patients with elevated levels. That could make a difference for some patients, Smith said.
Last week, Smith and her colleagues presented work at a Society of Gynecologic Oncology meeting proposing a new lower threshold for the blood test that would work better across all populations. The work could lead to changes in guidelines.
'New thresholds for referral will ensure that all patients get in for rapid care when ovarian cancer is suspected,' Smith said.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Refinery29
2 hours ago
- Refinery29
A new editorial destination dedicated to conversations and content about health and wellness issues of interest to Black women.
A new editorial destination dedicated to conversations and content about health and wellness issues of interest to Black women.

Yahoo
3 hours ago
- Yahoo
UnitedHealth Group received multiple bids for Latin American operations
-- UnitedHealth Group (NYSE:UNH) is considering several offers for its Latin American operations, according to a Reuters report on Monday. The move comes as the largest U.S. health insurer faces challenges that include the departure of its CEO and an alleged criminal accounting investigation. The insurer has been attempting to leave Latin America since 2022, with the sale of its Banmedica subsidiary becoming more urgent in recent months due to increasing pressures on multiple fronts, the report said. So far, UnitedHealth has reportedly received four preliminary bids for Banmedica, which operates in Colombia and Chile, with an estimated value of about $1 billion. In May, UnitedHealth's shares dropped 25.5%, and the year-to-date decline stands at 40%. The company withdrew from Brazil in 2023 and from Peru in March 2025. It aims to secure around $1 billion for Banmedica's operations in Colombia and Chile. The company anticipates setting a deadline for final proposals as early as July. The bids reportedly include offers from Washington, D.C.-based private equity firm Acon Investments, Sao Paulo-based private equity firm Patria Investments, Texas non-profit health organization Christus Health, and Lima-based healthcare and insurance provider Auna. The report mentioned that Auna is currently in discussions with a financial partner. Related articles UnitedHealth Group received multiple bids for Latin American operations Tesla shares slip after double downgrade amid Trump feud fallout What are the three big things in markets now? RBC weighs in
Yahoo
5 hours ago
- Yahoo
Dementia Risk Declining With Each Generation, Says Promising New Study
Dementia cases are on the rise around the world. In 2021, 57 million people were living with one of the neurodegenerative diseases under the dementia umbrella, and by 2050, that number is expected to reach 153 million. But a new study suggests the tides may be turning, with younger generations facing lower risks for the disease as they age. The research team, led by economist Xiaoxue Dou from the University of Queensland in Australia, ran a cross-sectional observational study using health survey data from the US, Europe and England: one that's representative of cross-sections of the populations involved at a single point in time, and based on observational data. The researchers only used variables that were available across all the survey data to estimate participants' dementia status, to compensate for any missing observations. "Birth cohorts born more recently were less likely to develop dementia in all three regions, albeit at different rates," the authors state in a journal article. "This decreasing trend was more pronounced among women than men." They particularly focused on people aged 71 years or older, with the data sorted into age groups spanning four years. Compared with the older groups, younger cohorts had lower age-specific dementia prevalence rates: 21.2 percent for those in the US study; 38.9 percent in the European study; and 28.3 percent in England. "For example, in the US, among people aged 81 to 85, 25.1 percent of those born between 1890-1913 had dementia, compared to 15.5 percent of those born between 1939-1943," economist and co-author Sabrina Lenzen of the University of Queensland told Nicola Davis at The Guardian. The team cautions their data may not accurately reflect what is happening in minority groups. But the findings suggest that, while aging populations globally will probably mean greater numbers of people living with dementia, the percentage of people affected may actually be decreasing, at least among the groups studied. This generational decrease in dementia risk, the study's authors write, "has important implications for health care planning, long-term care policies, and workforce requirements in aging populations." This research was published in JAMA Network Open. Several Psychiatric Disorders Share The Same Root Cause, Study Finds New Smart Dental Floss Can Detect Your Stress From Saliva Gluten Intolerance vs Celiac Disease: Experts Reveal The Key Differences